Prescription Drug Abuse

whitePaper | June 27, 2022

Following on from our review of trends in the current pharmaceutical R&D pipeline this supplement takes a look at the industry’s success stories of 2021

whitePaper | October 13, 2022

In our previous edition of the Clinical Trials Roundup1, we explored the acute disruptions that the COVID-19 pandemic brought to the clinical trials landscape in 2020.

whitePaper | May 24, 2022

Our proprietary nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics.

whitePaper | November 18, 2022

Small molecule drug development has changed substantially in recent years. With the heightened focus on molecularly targeted therapies, small molecule active pharmaceutical ingredients (APIs).

whitePaper | July 8, 2022

Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.